One in every eight people on Earth is living with obesity.
By 2035, that number is projected to climb to four billion—effectively half the human population.
The consequences are staggering. Complications linked to high BMI claim a life every six seconds.
What was once just a “lifestyle issue” is now one of the most powerful drivers of global disease. It is fueling diabetes, cardiovascular conditions, cancer, and metabolic disorders.
“8 Billion Reasons to Act”
For World Obesity Day 2026, the World Obesity Federation has set the theme: “8 Billion Reasons to Act.”
The message signals a shift from stigma toward science. From blame toward biology. From one-size-fits-all dieting toward precision metabolic medicine.
And the urgency is backed by numbers.
The global reality check
The latest data from the World Health Organisation (WHO) and the World Obesity Federation show a sharp upward trajectory:
- Current reach: Approximately 3 billion people are living with overweight or obesity today.
- The 2035 forecast: By 2035, half the global population—roughly 4 billion people—is projected to be living with overweight or obesity.
- Childhood impact: Over 400 million children and adolescents are currently affected. Since 1975, obesity rates among school-aged children have increased nearly fivefold.
- Economic cost: The global economic impact of obesity is estimated to reach $3.23 trillion by 2030.
This isn’t just a healthcare issue; It’s an economic, social, and generational crisis.
And metabolic health innovation is stepping up to address the crisis.
Metabolic health companies transforming obesity care
Knownwell
Founders: Brooke Boyarsky Pratt and Dr Angela Fitch
Year: 2022 | Location: Boston, USA
Knownwell provides “hybrid” care through both virtual and physical clinics, offering patients a dedicated team of doctors and nutritionists who specialise in metabolic health without judgment. They are fixing the broken patient experience by treating the person, not just the scale.
Structure Therapeutics
Founders: Raymond Stevens
Year: 2016 | Location: San Francisco, USA
Structure Therapeutics is making advanced weight-loss treatments more affordable. They are developing “small-molecule” oral pills that are easier and cheaper to manufacture than current injections, which could help expand access to obesity care in lower-income countries.
Viking Therapeutics
Founders: Brian Lian and Michael Dinerman
Year: 2012 | Location: San Diego, USA
We admire Viking Therapeutics for their “dual-acting” approach to weight loss. Their lead drug targets two different appetite hormones at once, and they are giving patients more choice by developing both a weekly injection and a convenient once-daily pill.
BioAge Labs
Founders: Kristen Fortney and Eric Mogen
Year: 2015 | Location: Richmond, USA
While many weight-loss drugs cause people to lose muscle alongside fat, BioAge Labs is developing a therapy that preserves muscle strength, ensuring that weight loss leads to better physical function, not just a lower BMI.
Kailera Therapeutics
Founders: Ron Renaud
Year: 2024 | Location: San Diego, USA
Kailera Therapeutics is focused on creating treatments that are more potent than the first wave of weight-loss injections but with significantly fewer side effects like nausea.
Kallyope
Founders: Charles Zuker, Tom Maniatis, and Richard Axel
Year: 2016 | Location: New York, USA
Instead of just suppressing appetite, Kallypope identifies the specific signals sent from the digestive tract to the brain to naturally regulate metabolism and sugar levels.
The road ahead
“8 Billion Reasons” is more than a campaign line.
It represents eight billion lives that deserve access to evidence-based care without stigma, without misinformation, and without systemic barriers.
As these therapies move from labs to pharmacies, the next phase of obesity care will not only be about weight loss. It will incorporate metabolic health, longevity and vitality.
By 2027, the conversation will likely shift from whether we can treat obesity to how we can ensure the whole world has access to these life-saving breakthroughs.
-By Rohini Kundu and the AHT Team
